Cleveland BioLabs to Report Second Quarter 2014 Financial Results and Provide Operational Update on August 7
29. Juli 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jul 29, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on August 7, 2014, it will report its financial results for the second quarter ended June 30,...
Cleveland BioLabs Reduces Debt With $3.5 Million At-the-Market Private Placement of Unregistered Stock
18. Juni 2014 09:25 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jun 18, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it entered into a securities purchase agreement (the "Purchase Agreement") with Dr. Mikhail...
Cleveland BioLabs Announces Compensation Reductions for Co-Founders and Directors; New Board Nominees
09. Mai 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - May 9, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that two of the Company's co-founders, Chief Executive Officer, Yakov Kogan and Chief Scientific...
Cleveland BioLabs Reports First Quarter 2014 Financial Results and Development Progress
08. Mai 2014 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - May 8, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2014.
...
Cleveland BioLabs to Report First Quarter 2014 Financial Results and Provide Operational Update on May 8
29. April 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 29, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on May 8, 2014, it will report its financial results for the first quarter ended March 31,...
Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102
16. April 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 16, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally...
CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting
01. April 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 1, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced two upcoming poster presentations at the 2014 American Association for Cancer Research (AACR) Annual...
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2013 Financial Results and Development Progress
11. März 2014 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Mar 11, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December 31,...
Cleveland BioLabs to Report Fourth Quarter and Fiscal 2013 Financial Results and Provide Operational Update on March 11
27. Februar 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 27, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on March 11, 2014, it will report its financial results for the fourth quarter and...
Cleveland BioLabs to Present at 2014 BIO CEO & Investor Conference
04. Februar 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the 2014 BIO CEO & Investor Conference, February...